Altimmune. which can be found using ticker (ALT) have now 8 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The target price High/Low ranges between 50 and 20 calculating the average target price we see $29.38. Given that the stocks previous close was at $10.96 this would indicate that there is a potential upside of 168.1%. The 50 day moving average now sits at $13.11 and the 200 day MA is $12.59. The market capitalization for the company is $543m. You can visit the company’s website by visiting: https://altimmune.com
The potential market cap would be $1,454m based on the market consensus.
Altimmune., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune. in September 2015. Altimmune. was founded in 1997 is headquartered in Gaithersburg, Maryland.
The company is not paying dividends at this time.
